Tandklinikken CS ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  2.2% 2.2% 2.2% 2.2% 2.2%  
Bankruptcy risk  12.1% 7.5% 7.4% 7.8% 8.6%  
Credit score (0-100)  19 31 32 30 29  
Credit rating  BB BB BBB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  201 734 1,035 790 656  
EBITDA  118 168 116 1.7 -6.0  
EBIT  85.8 112 54.1 -60.4 -53.9  
Pre-tax profit (PTP)  82.5 104.4 48.2 -60.3 -55.1  
Net earnings  63.6 79.3 36.2 -46.5 -62.5  
Pre-tax profit without non-rec. items  82.5 104 48.2 -60.3 -55.1  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  149 243 181 119 71.2  
Shareholders equity total  150 229 265 219 156  
Interest-bearing liabilities  91.6 94.0 108 18.0 18.3  
Balance sheet total (assets)  315 423 485 361 268  

Net Debt  91.5 -37.5 -146 -139 -150  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  201 734 1,035 790 656  
Gross profit growth  17.6% 264.5% 40.9% -23.7% -16.9%  
Employees  0 0 0 0 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  315 423 485 361 268  
Balance sheet change%  51.4% 34.3% 14.5% -25.5% -25.7%  
Added value  117.9 167.5 116.2 1.7 -6.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  2 39 -124 -124 -96  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  2.0 3.0 4.0 -1.0 -2.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  42.6% 15.3% 5.2% -7.6% -8.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  32.8% 30.4% 11.9% -14.3% -17.1%  
ROI %  40.1% 38.7% 15.2% -19.6% -26.1%  
ROE %  53.8% 41.8% 14.6% -19.2% -33.3%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  47.6% 54.2% 54.8% 60.7% 58.3%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  77.6% -22.4% -125.6% -7,932.3% 2,486.6%  
Gearing %  61.0% 41.0% 40.7% 8.2% 11.7%  
Net interest  0 0 0 0 0  
Financing costs %  3.6% 8.4% 5.8% 0.0% 8.2%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.8 0.7 1.2 1.3 1.6  
Current Ratio  0.8 0.7 1.2 1.3 1.6  
Cash and cash equivalent  0.0 131.5 254.0 156.7 167.9  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -25.3 -53.8 41.1 44.4 64.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 -3  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 -3  
EBIT / employee  0 0 0 0 -27  
Net earnings / employee  0 0 0 0 -31